Corrections to “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer”

Autor: Wu, Y., Amonkar, M.M., Sherrill, B.H., O'Shaughnessy, J., Ellis, C., Baselga, J., Blackwell, K.L., Burstein, H.J.
Zdroj: In Annals of Oncology June 2019 30(6):1019-1019
Databáze: ScienceDirect